Business Context and Reporting Period
Company: Outlook Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 8, 2020
Reporting Period: Event date October 8, 2020; Grace period extends to April 6, 2021.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on stock listing compliance.
Material Changes
On October 8, 2020, the Company received notification from Nasdaq that its common stock bid price closed below the minimum $1.00 requirement for 30 consecutive business days ended October 7, 2020, violating Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has a 180-day grace period (through April 6, 2021) to regain compliance.
- Compliance Requirement: The stock must close at or above $1.00 per share for a minimum of 10 consecutive business days on or before April 6, 2021.
- Current Status: The notice has no immediate effect on the listing or trading of the stock.
- Delisting Risk: If compliance is not achieved within the initial 180 days (and any potential additional 180-day period), the stock will be subject to delisting.
- Management Action: The Company intends to monitor the bid price and may consider available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of OTLK to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to determine if the initial compliance window is met.
- Review future filings for announcements regarding reverse stock splits or other corporate actions intended to raise the share price.
- Confirm the Company's intent to cure the deficiency if the initial 180-day period expires without compliance.